288 related articles for article (PubMed ID: 17588130)
1. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Alacqua M; Trifirò G; Arcoraci V; Germanò E; Magazù A; Calarese T; Di Vita G; Gagliano C; Spina E
Pharm World Sci; 2008 Jan; 30(1):44-50. PubMed ID: 17588130
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic medication use in children and adolescents in an inpatient setting.
Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V
Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844
[TBL] [Abstract][Full Text] [Related]
3. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
4. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Lam D; Gorman DA; Patten S; Pringsheim T
Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
[TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia associated with psychotropics--a review.
Madhusoodanan S; Parida S; Jimenez C
Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
Hill L; Lee KC
Ann Pharmacother; 2013 Jan; 47(1):75-89. PubMed ID: 23341158
[TBL] [Abstract][Full Text] [Related]
7. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings.
Rani FA; Byrne PJ; Murray ML; Carter P; Wong IC
Drug Saf; 2009; 32(4):325-33. PubMed ID: 19388723
[TBL] [Abstract][Full Text] [Related]
8. [Psychopharmacological treatment of behavioral and psychological symptoms in dementia].
Lolk A; Gulmann NC
Ugeskr Laeger; 2006 Oct; 168(40):3429-32. PubMed ID: 17032610
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Nurnberg HG; Thompson PM; Hensley PL
J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
[TBL] [Abstract][Full Text] [Related]
11. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
[TBL] [Abstract][Full Text] [Related]
12. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.
Wheeler A
N Z Med J; 2006 Jul; 119(1237):U2055. PubMed ID: 16862201
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
15. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK.
Murray ML; Thompson M; Santosh PJ; Wong IC
Drug Saf; 2005; 28(12):1151-7. PubMed ID: 16329717
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk from psychotropic medications: a population-based analysis.
Bolton JM; Metge C; Lix L; Prior H; Sareen J; Leslie WD
J Clin Psychopharmacol; 2008 Aug; 28(4):384-91. PubMed ID: 18626264
[TBL] [Abstract][Full Text] [Related]
17. Neonatal complications after intrauterine exposure to SSRI antidepressants.
Prescrire Int; 2004 Jun; 13(71):103-4. PubMed ID: 15233148
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Schneeweiss S; Patrick AR; Solomon DH; Dormuth CR; Miller M; Mehta J; Lee JC; Wang PS
Pediatrics; 2010 May; 125(5):876-88. PubMed ID: 20385637
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
Curran S; Turner D; Musa S; Wattis J
Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
[TBL] [Abstract][Full Text] [Related]
20. [Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
Kozyrev VN; Smulevich AB; Drobizhev MIu; Kraeva GK; Kubrakov MA
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):25-32. PubMed ID: 14681962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
